Through activating Pyk2, elevated ErbB‐2 could increase the ERK/MAPK activity and enhance cell adhesive ability and metastasis in human prostate cancer (PCa), while FAK isn't correlated with PCa cell adhesive ability (Yuan et al., 2007). Here, ERBB2 is linked to posterior cortical atrophy.